|
Aug 28
|
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
|
|
Jun 27
|
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
|
|
Jun 14
|
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
|
|
May 15
|
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
|
|
May 10
|
Monte Rosa Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview
|
|
May 9
|
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 2
|
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
|
|
Apr 10
|
Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why
|
|
Apr 4
|
Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?
|
|
Mar 22
|
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why
|
|
Mar 19
|
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know
|
|
Mar 16
|
Monte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial Results
|
|
Mar 15
|
Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?
|
|
Mar 14
|
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
|
Mar 11
|
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
|
|
Jan 16
|
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street
|
|
Jan 3
|
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Aug 10
|
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
|